AzTrials
AzTrials

Severe Acute Malnutrition in ChildhoodPhase 3BRIGHTSAMNCT06781918

Severe Acute Malnutrition and Child Development Clinical Trial in Mwanza

A Phase 3 study testing Ready to Use Therapeutic Food (RUTF) and Psychosocial stimulation in people with Severe Acute Malnutrition in Childhood, run by National Institute for Medical Research, Tanzania at 1 site in Tanzania.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This is a randomized clinical trial to learn whether ready-to-use therapeutic foods enriched with choline and docosahexaenoic acid (DHA) together with psychosocial stimulating activities work well to improve child development in children with severe acute malnutrition(SAM). Read more about this study

Who is it for?
Ages 6 to 36 months
Conditions the study is for
Severe Acute Malnutrition in Childhood
What is being tested?
Ready to Use Therapeutic Food (RUTF) and Psychosocial stimulation
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
800 participants
Where
1 siteTanzania
Study dates
3 Feb 2025to 14 May 2026
Phase
Phase 3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 36 months
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Age from 6-36 months.
  • Consent given by a caregiver older than 18 years.
  • Diagnosed with severe acute malnutrition (MUAC\<115 mm, or WHZ ≤-3 or bipedal pitting edema).
  • Eligible for RUTF treatment (expanded below).

Who cannot join

  • Conditions preventing the child from receiving interventions, e.g., peanut butter allergy or cleft palate.
  • Moderate or severe disability which significantly affects normal child development (e.g., cerebral palsy or hydrocephalus), identified using a standardized screening form.
  • Children of families not living in the area or planning to move from the area within the follow-up period

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

George PrayGod, MD, PhD contact

+255714226305

george.praygod@nimr.or.tz

Belinda Kweka, MD, MSc contact

+255765025170

belinda.kweka@nimr.or.tz

Tanzania1 site
  • National Institute for Medical Research

    Mwanza

    George PrayGod, MD, PhD, +255714226305, george.praygod@nimr.or.tz

    Belinda Kweka, MD, MSc, +255765025170, belinda.kweka@nimr.or.tz

Other trials in Tanzania

About this study

Official title: BRAIN DEVELOPMENT, GROWTH AND HEALTH IN CHILDREN WITH SEVERE ACUTE MALNUTRITION

This is a randomized clinical trial to learn whether ready-to-use therapeutic foods enriched with choline and docosahexaenoic acid (DHA) together with psychosocial stimulating activities work well to improve child development in children with severe acute malnutrition(SAM). The overall question this trial aims to answer is can the health and development outcomes of children with SAM be improved through optimized nutritional treatment and integrated psychosocial support.

Researchers will compare the new ready-to-use therapeutic food and an integrated psychosocial stimulation to a standard look-alike nutritional supplement that contains no additional nutrients being investigated and the standard nutritional counseling given locally and assess its effects on child development in children with severe acute malnutrition.

Read more

Participants will:

  • Be given the trial interventions which will be delivered over 12 weeks
  • After the 12 weeks of intervention, participants will return for outcome evaluations (week 12 study visit), which will be repeated at follow-up visits after 24 and 48 weeks.
Read the detailed description

Background Estimated, 13.6 million children were affected by severe acute malnutrition (SAM) in 2022. Early childhood is a critical period of brain development and children exposed to malnutrition in early life have poorer school performance and lower income in adult life. Introduction of Ready to use therapeutic foods (RUTF) has greatly improved the nutritional recovery of children with SAM. However, SAM remains associated with adverse effects on child cognitive and social development. The balance in the RUTF between polyunsaturated n-6 and n-3 essential fatty acids (EFAs) in RUTF has been questioned. Essential fatty acid (EFA) status is associated with child development, and children given the standard RUTF do not improve their n-3 EFA status after recovery.

A trial in Malawi found a positive effect on cognitive scores six months after completing nutritional therapy with RUTF with added preformed docosahexaenoic acid (DHA), a long-chain polyunsaturated fatty acid (PUFA) of the n-3 series, which is essential for neural growth. There is also a potential for improving the content of other nutrients of importance for neurodevelopment in early childhood like choline, which is essential for neurotransmitter synthesis and phospholipids in the brain. Studies have indicated a synergistic relationship between n-3 EFAs and choline, suggesting that low levels of one or both may negatively impact cognition.

Deficits in child development associated with SAM are not only caused by inadequate diets. Families exposed to malnutrition are often affected by psychological distress, consequently children are likely to be offered little stimulation and responsive care. However, in practice, support for psychosocial stimulation and responsive caregiving is rarely offered during hospital-based treatment, and it is still not included in the guidelines for community-based treatment of SAM. The intensity of this intervention is difficult under the constraints of most health services in low- and middle-income countries (LMIC). More recent packages for promoting responsive care have shown some effects, but often not when implemented at scale or within systems of care.

In this study we hypothesize that optimized nutritional treatment and integrated psychosocial support can improve the health and development outcomes of children with SAM.

Specific objectives:

  1. to assess the effects of a modified RUTF and psychosocial stimulation, individually and combined, on attention, cognitive, motor, language and psycho-emotional development in children treated for SAM;
  2. to investigate the pathways of intervention effects on cognitive development by assessing the role of DHA and choline status in the child as well as caregiver factors which include caregiver-child interaction, home stimulation and maternal psychological distress;
  3. to assess how, why and for whom the modified RUTF and psychosocial interventions work within the trial context, perceptions of their feasibility of implementation within the routine health system, and the climate and environmental sustainability of interventions.

Methods:

This trial is designed as a 2x2 factorial randomized clinical trial to assess the effects of DHA and choline enriched vs. standard RUTF and psychosocial stimulation vs. standard counselling in management of SAM. Participants will be individually randomised to nutritional intervention arms and clusters will be randomized to psychosocial intervention arms.

The interventions will be delivered over a period of 12 weeks. After enrolment and baseline data collection, participants will receive their first RUTF sachets. They will then be requested to return to the study site for a total of seven visits during the intervention period to receive interventions. After the 12 weeks of intervention, participants will return for outcome evaluations (week 12 study visit), which will be repeated at follow-up visits after 24 and 48 weeks. The study will take place in Mwanza region, Tanzania. The trial will include children with uncomplicated SAM aged 6-36 months from eight health care facilities in Ilemela municipality, Nyamagana municipality and Magu district.

Outcomes:

The primary outcomes is the change in child development scores, which will be assessed at baseline, 12, 24 and 48 weeks and compared with intervention groups. These will assess gross, fine motor, language and psycho -emotional skills by validated tool called (MDAT) Malawi Development Assessment Tool) and neurocognitive function will be accessed by eye-tracking. Secondary outcomes will allow us to assess proximate effects of the interventions, which may mediate long-term effects on development

Analysis:

The primary analysis will be based on the intention-to-treat principle using available case data. The analysis will assess intervention effects based on the 2x2 factorial design by comparing changes in outcomes between baseline and intervention endline (i.e., 12 weeks) using a linear regression model adjusted for sex, age and month of inclusion to account for possible seasonal effects.

Secondary analysis will include assessment of intervention effects at 24- and 48-weeks follow-up using a linear mixed model to include repeated measurements. The models will include the baseline value of the outcome as fixed effect and participant as random effect to account for the correlation between measurements from the same participant. These models will also include adjustment for other variables as appropriate.

Secondary analyses will include per-protocol analyses to assess effects within groups with high compliance with the interventions

Ethics:

Ethical approval has been sought from the Medical Research Coordinating Committee (MRCC) of the National Institute for Medical Research in Tanzania and the London School of Hygiene and Tropical Medicine ethics committee.

Being tested
Ready to Use Therapeutic Food (RUTF), Psychosocial stimulation
Keywords
Severe acute malnutrition, Ready to use therapeutic food, Childhood development, Psychosocial stimulation, Choline, Docosahexaenoic acid (DHA)
Medical subject headings
Severe Acute Malnutrition

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Ready to Use Therapeutic Food (RUTF)Dietary supplement

    DHA \& Choline enriched RUTF The modified RUTF is a peanut butter paste that contains vegetable oil, skim milk powder, carbohydrates, vitamins, and minerals the same nutrients which are the same as the standard RUTF but is fortified additionally with 250 mg of choline and 200 mg of preformed DHA per 92-gram sachet.

    Standard RUTF The standard RUTF used in the BrightSAM trial is a peanut butter paste with vegetable oil, skim milk powder, carbohydrates, vitamins, and minerals that is intended to cover the child's total daily nutritional needs. Standard RUTF will be manufactured in compliance with the specifications recommended by the Codex Alimentarius Commission17.

  • Psychosocial stimulationBehavioural

    The psychosocial intervention has been developed and piloted for this study as a context-relevant adaptation from the WHO/UNICEF Care for Child Development package. It will be delivered in group sessions, where the primary caregiver will attend along with the child participating in the trial.

    During seven sessions of approximately two hours, caregivers will be trained on a variety of subjects which include; the first four sessions will be introductory and provide the basics of nutrition, the basics of psychosocial stimulation, and play and communication practices. We will build on the increasing experience of the caregivers and provide a deeper understanding of early child development.

    Standard nutritional counseling will adhere to national guidelines for pediatric management of severe acute malnutrition including nutritional counseling and psychosocial stimulation.

Study groups in NCT06781918
Study groupRoleWhat they receive
eRUTFExperimentalCholine and DHA enriched Ready to use therapeutic foods
Receives: Dietary Supplement: Ready to Use Therapeutic Food (RUTF)
sRUTFPlacebo comparatorStandard ready-to-use therapeutic foods
Receives: Dietary Supplement: Ready to Use Therapeutic Food (RUTF)
PSExperimentalPsychosocial stimulation
Receives: Behavioral: Psychosocial stimulation
sNCPlacebo comparatorStandard nutritional counseling and psychosocial stimualtion
Receives: Behavioral: Psychosocial stimulation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in MDAT scores

    Development will be assessed by validated methods and include:

    Gross motor, fine motor, language, and psycho-emotional skills assessed by the Malawi Development assessment tool (MDAT)

    Measured: Assessed at baseline, 12, 24 and 48 weeks

  2. Change in eye tracking scores

    Neurocognitive function assessed by eye-tracking technique

    Measured: Baseline, 12, 24 and 48 weeks

Secondary outcomes (20)
  1. Level of caregiver stimulation and support

    Caregiver stimulation and support assessed by Observations of Mother and Child Interactions (OMCI) questionnaire

    Measured: Assessed at baseline, 12, 24 and 48 weeks

  2. Fatty acid composition

    • Fatty acid composition assessed by gas chromatography

    Measured: at baseline and at week 12, and week 48

  3. Mid upper arm circumference (MUAC)

    • MUAC assessed using non-stretchable tape measure

    Measured: Baseline, weekly, 12, 24 and 48 weeks

  4. Mortality

    Proportion of children who die during follow-up

    Measured: 12, 24 and 48 weeks

  5. Process evaluation

    The process evaluation will examine the following aspects of the interventions:

    • Implementation
    • Mechanisms
    • Context
    • Acceptability
    • Feasibility of implementation within the health system
    • Programme theory

    Measured: Interviews will be conducted after the last PS session ( Week 11) , and where possible, again with the same caregivers at long term follow-up (week 24 and 48).

  6. Levels of choline

    Levels of choline and related metabolites assessed by mass spectrometry

    Measured: Baseline, 12, 24 and 48 weeks

  7. C-reactive protein (CRP)

    Serum CRP assessed as a marker of systemic inflammation

    Measured: Baseline, 12, 24 and 48 weeks

  8. Ferritin

    Serum ferritin assessed as marker of iron status

    Measured: Baseline, 12, 24 and 48 weeks

  9. Level of Alanine transaminase

    Serum alanine transaminase as a marker of liver function

    Measured: Baseline, 12, 24 and 48 weeks

  10. Level of Aspartate transaminase

    Serum aspartate transaminase assessed as a marker of liver function

    Measured: Baseline, 12, 24 and 48 weeks

  11. Level of maternal psychological distress

    Maternal psychological distress assessed by Patient Health Questionnaire 9 (PHQ-9)

    Measured: Baseline, 12, 24 and 48 weeks

  12. Status of the learning environment

    The status of learning environment assessed by the Family Care Indicators (FCI) questionnaire

    Measured: Baseline, 12, 24 and 48 weeks

  13. Status of maternal social support framework

    The status of maternal social support framework assessed by the Multidimensional Scale of Perceived Social Support questionnaire

    Measured: Baseline, 12, 24 and 48 weeks

  14. Morbidity

    . Proportion of children with one or multiple illness episodes during follow-up

    Measured: 12, 24 and 48 weeks

  15. - Weight-for-height z-score (WHZ)

    • Weight-for-height z-score (WHZ) based on length/height (m) and weight (kg) measurements'

    Measured: Baseline, 12, 24 and 48 weeks

  16. Height-for-age z-score (HAZ) , based on length/height and age)

    Height-for-age z-score (HAZ) assessed based on length/height (m) and age (month)

    Measured: Baseline, 12, 24 and 48 weeks

  17. Rate of nutritional recovery at the end of intervention period

    Rate of nutritional recovery at the end of intervention period, defined as WHZ > -2 and MUAC > 125 mm, and no bilateral pitting oedema for two weeks

    Measured: 12

  18. Proportion relapsing to moderate acute malnutrition (MAM) after recovery

    Proportion relapsing to moderate acute malnutrition (MAM) after recovery, measured as WHZ ≤ -2 and >-3 or MUAC ≤ 125 and >115mm)

    Measured: 12 weeks

  19. Proportion relapsing to SAM after recovery

    Proportion relapsing to SAM after recovery, measured as WHZ <-3, MUAC <115mm or presence of nutritional oedema, assessed at any caregiver-initiated contacts to the study site at any point during the 48 weeks of follow-up and at study visits at 24 and 48 weeks

    Measured: Any time point, 24 and 48 weeks

  20. Implementation evaluation

    The implementation component will assess

    • The fidelity of implementation of each component of the intervention,
    • The dose (amount, frequency) of each component delivered to the children,
    • Any adaptations to the intervention and why these were made,
    • The reach of the interventions, provider and caregiver experience
    • Perceptions, mechanisms and any unintended consequences.

    Measured: Interviews will be conducted after the last PS session ( Week 11) , and where possible, again with the same caregivers at long term follow-up (week 24 and 48).

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Jan 2025
  2. Study start3 Feb 2025 (estimated)
  3. Primary completion14 Nov 2025 (estimated)
  4. Study completion14 May 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Factorial
Model description
This is a 2x2 factorial randomized clinical trial which aims to study the effects of DHA and choline enriched ready to use therapeutic foods and psychosocial stimulation in the management of children with severe acute malnutrition.
Masking
Double blind
Who is masked
Participant, Care provider
Enrolment
800 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06781918
Sponsor's protocol ID
DFC file no. 23-13-RH
Other IDs
DFC file no. 23-13-RH
Acronym
BRIGHTSAM
Status last verified
Jan 2025
First submitted
3 Dec 2024
Last updated
17 Jan 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Grantham-McGregor S, Stewart ME, Schofield WN. Effect of long-term psychosocial stimulation on mental development of severely malnourished children. Lancet. 1980 Oct 11;2(8198):785-9. doi: 10.1016/s0140-6736(80)90395-5.

    PubMed 6107460
  • Olsen MF, Iuel-Brockdorff AS, Yameogo CW, Cichon B, Fabiansen C, Filteau S, Phelan K, Ouedraogo A, Wells JC, Briend A, Michaelsen KF, Lauritzen L, Ritz C, Ashorn P, Christensen VB, Gladstone M, Friis H. Early development in children with moderate acute malnutrition: A cross-sectional study in Burkina Faso. Matern Child Nutr. 2020 Apr;16(2):e12928. doi: 10.1111/mcn.12928. Epub 2019 Dec 11.

    PubMed 31823490
  • Stephenson K, Callaghan-Gillespie M, Maleta K, Nkhoma M, George M, Park HG, Lee R, Humphries-Cuff I, Lacombe RJS, Wegner DR, Canfield RL, Brenna JT, Manary MJ. Low linoleic acid foods with added DHA given to Malawian children with severe acute malnutrition improve cognition: a randomized, triple-blinded, controlled clinical trial. Am J Clin Nutr. 2022 May 1;115(5):1322-1333. doi: 10.1093/ajcn/nqab363.

    PubMed 34726694
  • Gera T, Pena-Rosas JP, Boy-Mena E, Sachdev HS. Lipid based nutrient supplements (LNS) for treatment of children (6 months to 59 months) with moderate acute malnutrition (MAM): A systematic review. PLoS One. 2017 Sep 21;12(9):e0182096. doi: 10.1371/journal.pone.0182096. eCollection 2017.

    PubMed 28934235
  • Lelijveld N, Jalloh AA, Kampondeni SD, Seal A, Wells JC, Goyheneix M, Chimwezi E, Mallewa M, Nyirenda MJ, Heyderman RS, Kerac M. Brain MRI and cognitive function seven years after surviving an episode of severe acute malnutrition in a cohort of Malawian children. Public Health Nutr. 2019 Jun;22(8):1406-1414. doi: 10.1017/S1368980018003282. Epub 2018 Dec 3.

    PubMed 30501662
  • Hoddinott J, Behrman JR, Maluccio JA, Melgar P, Quisumbing AR, Ramirez-Zea M, Stein AD, Yount KM, Martorell R. Adult consequences of growth failure in early childhood. Am J Clin Nutr. 2013 Nov;98(5):1170-8. doi: 10.3945/ajcn.113.064584. Epub 2013 Sep 4.

    PubMed 24004889

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Ready to Use Therapeutic Food (RUTF) and Psychosocial stimulation in people with Severe Acute Malnutrition in Childhood, run by National Institute for Medical Research, Tanzania at 1 site in Tanzania.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 17 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Tanzania. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact George PrayGod, MD, PhD (+255714226305, george.praygod@nimr.or.tz), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in MDAT scores (time frame: Assessed at baseline, 12, 24 and 48 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06781918, which also lists 6 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jan 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in